## Flowsheet for INTERMEDIATE Recurrence Risk\* PTC/FTC Patients

| Patient Name: ug/L Post-Operative (unstimulated) Tg: ug/L |      |       |       | HSC: L or R hemithyroidectomy/Total (circle): |        |        |        |        |        |        |        |        |        |        |        |
|---|------|-------|-------|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|   |      |       |       | Completion hemithyroidectomy:                 |        |        |        |        |        |        |        |        |        |        |        |
| □RAI Administered? Dose:mC                                |      |       | _ mCi | Date: Date Ca support discontinued:           |        |        |        |        |        |        |        |        |        |        |        |
|   | 1 mo | 3 mos | 6 mos | 9 mos   | 12 mos | 15 mos | 18 mos | 21 mos | 24 mos | 30 mos | 36 mos | 42 mos | 48 mos | 54 mos | 60 mos |
| Date Due:   |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |
| Levothyroxine dose (mcg)                                  |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |
| Serum TSH<br>Free T4                                      |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |
| Unstim. Tg Anti-Tg  |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |
| Stimulated Tg,<br>Anti-Tg                                 |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |
| Diagnostic Whole Body<br>Scan                             |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |
| Neck Ultrasound (indicate<br>- or + findings)             |      |       |       |   |        |        |        |        |        |        |        |        |        |        |        |

## **ATA Surveillance Guidelines for Intermediate Risk Patients:**

- TSH Goal 0.1-0.5 mIU/L for 3-5 years, then 0.5-1 if patient remains stably in remission.
- U/S at 6 months post-op & then q6-12 mos for 5 yrs, TFT's and <u>unstimulated Thyroglobulin</u> every 3-6 mos for 3 yrs and then annually
- IF treated with  $^{131}$ I  $\rightarrow$  consider TSH-stimulated Tg  $\pm$   $^{123}$ I scan after 1-2 years.

<sup>\*&</sup>quot;Intermediate Risk"→ Extensive N1a (central neck) or minimal N1b (lateral neck) lymph node metastases